The VAD Journal: The journal of mechanical assisted circulation and heart failure

Peer-Reviewed Original Research

Decrease in Driveline Infections with
Change in Driveline Management
Protocol
Saima Aslam*, Jennifer Dan, Amanda Topik, Michael Belyk,
Francesca Torriani, Randy Taplitz, Jorge Silva-Enciso, Denise
Barnard, Barry Greenberg, Jack Copeland, Victor Pretorius, Eric
Adler
University of California, San Diego, CA
* Corresponding author: saslam@ucsd.edu
Citation: Aslam, S. et al.
(2016)."Decrease in Driveline
Infections with Change in
Driveline Management Protocol”

Abstract
Background

The VAD Journal, 2. doi:

http://dx.doi.org/10.13023/VAD.
2016.03
Editor-in-Chief: Maya Guglin,
University of Kentucky
Received: February 9, 2016

Driveline infections (DLI) are a significant cause of morbidity and mortality in
ventricular assist device (VAD) recipients. We compared driveline infection (DLI)
rate after an institutional change in driveline management protocol.
Methods

Accepted: February 20, 2016
Published: March 3, 2016
© 2016 The Author(s). This is an
open access article published
under the terms of the Creative
Commons AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original author(s) and the
publication source are credited.

We retrospectively reviewed records of left VAD recipients at our institution,
based on driveline management. Group 1: daily driveline dressing change
consisting of chlorhexidine cleansing, sterile 4x4 gauze, and use of an abdominal
binder. Group 2: Dressing change every 3 days consisting of chlorhexidine
cleansing, non-sterile silver-impregnated foam with overlying clear dressing, and
use of a driveline anchor. Follow-up was censored at first DLI, device removal,
transplant or death. Additionally, Group 1 patients’ follow-up was censored when
the change in protocol occurred. Statistical analysis: Student’s t-test, Fisher’s
exact test, Kaplan-Meier curve and log-rank test.
Results
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DLI occurred in 16% of 88 VAD recipients (Group 1 n=24, Group 2 n=64). The
new driveline management protocol resulted in significantly fewer DLI in Group 2
(6.3% vs. 41.7%, p<0.0001)
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Conclusions
An updated driveline management protocol demonstrated significant reduction in
DLI at our institution. Studies evaluating the optimal approach for driveline
management are needed in order to develop a standardized regimen aimed at
lowering the risk of DLI.
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prevention
Introduction
Heart failure is a major cause of morbidity and mortality in the United States,
where about 5.1 million people are living with heart failure; half of these patients
will die within 5 years of diagnosis.(1) Ventricular assist devices (VADs) have
emerged as a standard of care for patients with end-stage heart failure, both as a
bridge to transplant (BTT) and as destination therapy (DT) with actuarial survival
of 80% at one year and improved quality of life.(2) However, VAD use is
associated with various complications, including percutaneous driveline
infections (DLIs).
Overall rate of DLI in various studies ranges from 14-48%; infections appear to
be cumulative over time with increased DLI noted with greater duration of VAD
support.(3-5) DLIs negatively impact recipient quality of life; potential
complications include development of sepsis/ bacteremia, hospital readmission(s), pump pocket infection, re-operation, and decreased survival.(3, 4,
6) Risk factors for DLI include obesity, diabetes, younger age, trauma to the
driveline site, and length of implantation.(4-6)
Currently there are no standardized protocols for the type of driveline dressing
used or the frequency of change; VAD centers in the United States use a variety
of protocols.(7) Current measures to decrease the rate of DLI include tunneling
the driveline within the abdominal subcutaneous tissue, stabilization of the
device, and use of various dressing change protocols. Stabilization of the
driveline has generally been achieved with the use of abdominal binders. A
recent survey of VAD coordinators among 38 US centers showed that 70% of the
responding centers used a stabilization belt.(7) Several recent papers discuss
alternative stabilization techniques for the driveline such as use of StatLock
system with a silicone suture, Centurion Foley anchor, or Hollister tube holder
instead of the abdominal binder that is easier and more comfortable for the
patient to use.(7, 8) The same survey also noted that there was no standard for
dressing change protocols in terms of agents used and the frequency of dressing
changes though 60% of programs reported daily dressing changes. It is also not
clear if sterile technique should be applied at each dressing change.
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We describe the results of a change in the management strategy of the driveline
and the resultant significant decrease in DLIs observed at our institution.

Methods
After obtaining IRB approval, we retrospectively reviewed medical records for all
patients that received a left ventricular assist device from 9/1/2010 to 5/30/2015
at our institution. The IRB determined that informed consent was not required.
We abstracted data regarding the indication for device placement, INTERMACS
profile, baseline demographics, driveline management protocol, development of
driveline infection and its microbiology, post-operative complications, length of
hospital stay, duration of follow-up, and mortality. INTERMACS profile is a
marker of severity of heart failure and ranges from 1-7; profile 1 is critical
cardiogenic shock and profile 7 is consistent with advanced New York Heart
Association functional class III heart failure.(9) We excluded all other infections
such as VAD pump infection, mediastinitis, bloodstream infection, pneumonia,
urinary tract infection etc.
Definition of DLI: We used the standardized definitions put forth by the
International Society of Heart and Lung Transplantation (ISHLT) in 2011.(10)
Briefly, findings on surgery (if performed), growth of an organism on aseptic
culture, clinical signs/ symptoms, and wound appearance are combined to define
a superficial or deep DLI. For purposes of our study, we combined superficial and
deep DLI into one category.
VAD surgery: During the study period, our center implanted two types of durable
continuous flow ventricular assist devices – HeartMate II (Thoratec Corporation,
Pleasanton, CA) and HeartWare HVAD system (HeartWare, Framingham, MA).
Two main cardiothoracic surgeons performed the surgeries according to
established surgical technique. The driveline was tunneled in the subcutaneous
tissue with the exit site generally on the right abdominal wall. The velour portion
of the driveline was consistently placed under the skin in all patients.
Perioperative antibiotic prophylaxis consisted of vancomycin and cefepime that
was started within one hour prior to surgical incision and continued for 48 hours
thereafter. Prior to 9/2012, we used cefazolin as peri-operative prophylaxis,
which was continued for 48 hours post-operatively as well.
Driveline Management Protocol: We compared two non-concurrent cohorts of
patients based on their driveline management protocol.
Group 1- The driveline dressing change occurred daily and consisted of
chlorhexidine cleansing (ChloraPrep® One-Step, CareFusion, USA) and sterile
4x4 gauze followed by the placement of an abdominal binder. This was the
management protocol for patients that underwent VAD implantation from
9/1/2010 to 8/31/2012.
Group 2 - The driveline dressing changes were done every 3 days and consisted
of chlorhexidine cleansing (ChloraPrep® One-Step, CareFusion, USA), silver-
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impregnated foam (Mepilex® Ag, Molnlycke Healthcare Sweden) which was then
covered by a clear dressing (Centurion® Sorbaview® Shield, Centurion Medical
Products Corp, USA) and placement of an “anchor” (Centurion® Foley Anchor,
Centurion Medical Products Corp, USA) to prevent excess driveline movement
(instead of the abdominal binder). This management protocol went into effect
from 9/1/2012 to the current time.
Patients and families were instructed on how to care for the driveline at home
prior to hospital discharge and this teaching was reiterated at clinic visits by the
VAD coordinators. If patients developed redness, pain, drainage from the
driveline and/ or fever or other symptoms consistent with sepsis, they were
thoroughly evaluated to look for a source of infection and possible VAD
involvement. This work-up included blood cultures, aseptic culture of drainage
from the driveline (if applicable) and imaging (echocardiogram/ computed
tomography scan and/ or ultrasound).
We censored follow-up at the occurrence of first driveline infection, removal of
the device, transplantation or death. In addition, follow-up of Group 1 patients
was censored at the time the institutional change in dressing protocol occurred;
thus Group 1 only includes the time at risk as the time the patient was
undergoing the management strategy for Group 1. Figure 1 shows pictures of
both types of dressings.
Figure 1. Pictures of the driveline dressing in Group 1 (a) and Group 2 (b).

Statistical analysis: Univariate analyses were performed via t test or Fischer’s
exact test as appropriate. Logistic regression was performed for multivariate
analysis of factors that were associated with development of DLI in univariate
analysis. Kaplan-Meier survival analysis was used for estimating freedom from
first DLI. Log-rank test was used to compare infection-free survival differences
among groups. Patients who did not experience DLI were censored if they died,
were transplanted, explanted for recovery, or lost to follow-up. We used Stata
(Statacorp, College Station, Texas) as the software for analysis.
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Results
During the study period, 88 patients underwent left VAD placement (64
HeartMate II, 24 HeartWare HVAD). Of these, 5 patients underwent device
exchange for device thrombosis (4 HeartMate II, 1 HeartWare HVAD) and 7
patients had concurrent right VADs (7 HeartWare HVAD). There were 24 patients
in Group 1 and 64 patients in Group 2.
Baseline characteristics at the time of VAD implantation are detailed in Table 1,
including demographics, INTERMACS profile, underlying cardiomyopathy, other
co-morbidities, basic laboratory parameters, and length of initial hospitalization at
which the device was placed. The main differences between the two groups were
in the indication for VAD implantation (Group 1 had 75% of DT patients vs.
46.9% in Group 2, p=0.029), the type of device (Group 1 had 100% HeartMate II
vs. 62.5% in Group 2, p<0.0001) and INTERMACS category (Group 1 had 8.3%
INTERMACS category 4 vs. 31.3% in Group 2, p=0.029). Other parameters,
including age, race, sex, underlying cardiac disease, co-morbidities, need for
hemodialysis, length of hospitalization at index surgery, and return to the
operating room were similar in both groups.
Table 1. Baseline demographics of the study population.
Group 1 patients underwent daily driveline dressing change consisting of
chlorhexidine cleansing and sterile 4x4 gauze followed by the placement of an
abdominal binder. Group 2 patients underwent driveline dressing changes every
3 days consisting of chlorhexidine cleansing followed by a non-sterile silverimpregnated dressing which was then covered by a clear dressing, and
placement of an “anchor” to prevent excess driveline movement (instead of the
abdominal binder).

Age in years, mean
(SD)
Male sex (%age)
Race (%age)
Caucasian
African-American
Asian
Other
Hispanic ethnicity
(%age)
INTERMACS profile at
time of implantation
1
2
3
4

Group 1
(n=24)
58.25 (14.9)

Group 2
(n=64)
58.2 (14)

p-value

17 (70.8%)

54 (84.4%)

NS
NS

18 (75%)
3 (12.5%)
2 (8.3%)
1 (4.2%)

31 (48.4%)
12 (18.8%)
5 (7.8%)
16 (25%)

4 (16.7%)

16 (25%)

NS

NS
0.021

4 (16.7%)
12 (50%)
6 (25%)
2 (8.3%)
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Indication
Bridge to transplant
Destination therapy
Type of VAD
HeartMate II
HeartWare
Primary disease
Ischemic
Non-ischemic
Co-morbidities at time of
VAD placement
Diabetes
CVA
Cirrhosis
COPD
Body Mass Index, mean
(SD)
Baseline laboratory
parameters (with SD)
Sodium, mmol/L
Creatinine, mg/dL
WBC, 103 /mm3
HCT, %
Platelets, 103 /mm3
Bilirubin, mg/dL
Albumin, g/dL
INR
HbA1c
Post-VAD dialysis
during index
hospitalization
Mean length of index
hospitalization in days,
(SD)
Previous cardiac
surgery
Return to operating
room within 30 days of
index surgery

0.029
6 (25%)
18 (75%)

34 (53.1%)
30 (46.9%)

24 (100%)
0

40(62.5%)
24 (37.5%)

<0.0001

NS
11 (45.8%)
13 (54.2%)

25 (39.1%)
39 (60.9%)

7 (29.2%)
0
0
2 (8.3%)
26.6 (4.3)

27 (42.2%)
4 (6.3%)
10 (15.6%)
11 (17.2%)
26 (0.7)

NS
NS
NS
NS
NS

133 (5.7)
1.4 (0.5)
8.8 (3.5)
34.5 (5.3)
205.5(53.7)
1.5 (1.4)
3.7 (0.4)
1.3 (0.3)
6.2 (0.6)
3 (12.5%)

132.8 (6.7)
1.4 (0.48)
8.6 (3.8)
32.5 (5.4)
199 (84.3)
1.4 (1.3)
3.6 (0.6)
1.5 (0.4)
6.2 (0.6)
5 (7.8%)

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

35.9 (35)

44.3(50.3)

NS

11 (45.8%)

17 (26.6%)

NS

4 (16.7%)

5 (7.8%)

NS

*INTERMACS profile 1 – critical cardiogenic shock; INTERMACS profile 2 –
progressive decline in heart failure despite intravenous inotropic support;
INTERMACS profile 3- stable heart failure but dependent on intravenous
inotropic support; INTEMACS profile 4- resting heart failure symptoms but
without intravenous inotropic support.
Driveline Infections: As seen in Table 2, the change in driveline management
protocol resulted in a significant reduction in driveline infections in Group 2 vs.
Group 1 (6.3% vs. 41.7%, p<0.0001) along with a significant decrease in the
incidence of DLI/ 1000 device days; 0.24 vs. 1.81, p= 0.0002. Kaplan-Meier
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survival curves (Figure 2) demonstrated significantly increased infection-free
survival in Group 2 patients; log-rank test, p=0.0003. The mean onset of DLI in
group 1 was 217.1 days vs 74.8 days in Group 2; this was not statistically
significant (p=0.12).
The overall mortality rate during the time of device placement was 11.4% (n=10)
and was unrelated to the development of a DLI. The relative risk reduction due
to the new driveline management protocol was 85% and the number needed to
treat was 2.82.
Table 2. Occurrence of driveline infections (DLI) in the two cohorts of patients.
Group 1 (n=24)
Group 2 (n=64)
p-value
No. of driveline
10 (41.7%)
4 (6.3%)
<0.0001
infections
Days of device follow230.8 (195.3)
258.2 (232.5)
0.61
up, mean (SD) *
DLI incidence/ 1000
1.81
0.24
0.0002
device days
DLI incidence/ 100
65.9
8.8
0.0002
patient years
*censored at protocol change, device removal/transplant, death or DLI
Figure 2. Kaplan-Meier estimates for freedom from driveline infection for the two
cohorts of patients undergoing different driveline management protocols; log-rank
test, p=0.0003

p=0.0003
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We also analyzed the rate of DLI, incidence of DLI/1000 device days as well as
log-rank survival analysis in the indication for transplant i.e. BTT vs. DT patients
(no statistical difference) and the type of device implanted i.e. HeartMate II vs.
HeartWare patients (no statistical difference). These results are shown in the
Appendix Tables 1 and 2. We also conducted a sensitivity analysis of DLI
occurrence including the indication for device implant as well as the type of
device used assuming a potential 10% misclassification error and specificity of
90%. In this sensitivity analysis, the only significant predictor of the outcome of
DLI was the Group assignment (OR 0.00085, 95% 7.29e-07- 0.99294; p=0.05
though a 95% CI that did not cross 1).
Risk factors for development of DLI: In univariate analysis, patient presence in
Group 2 was significantly lower in patients with a DLI (28.6% among patients with
a DLI vs. 81.1% in those without a DLI, p<0.0001). There was a trend towards
higher body mass index (BMI) in patients with DLIs vs. those that did not develop
a DLI (mean BMI 28.62 vs. 25.6, p=0.059). We did not find an association with
age, indication for VAD placement, INTERMACS category, device type,
underlying cardiac disease, length of initial hospital stay, various co-morbidities
including diabetes mellitus, post-operative need for hemodialysis, previous
cardiac surgery or return to the operating room within 30 days of VAD placement.
Baseline laboratory parameters at the time of VAD implantation including serum
sodium, creatinine, white blood cell count, platelets, bilirubin, and albumin were
similar in patients that developed DLI and those that did not. Patients that
developed DLI had a higher hematocrit (mean 36.6 vs. 32.4, p=0.008) and lower
INR (1.23 vs. 1.47; p=0.048) than those that did not develop a DLI in univariate
analysis.
The multivariate model included the driveline management group, BMI,
hematocrit and INR; only the driveline management strategy was associated with
development of DLI (OR 0.09, 95% CI 0.02-0.4, p=0.002) as shown in Table 3.
Table 3. Univariate and multivariate analysis of factors associated with
development of a driveline infection as the outcome (vs. no DLI)
Univariate analysis
p-value

Placement in
Group 2
BMI (mean)
HCT, %
(mean)
INR

28.6%
vs.
81.1%
28.6 vs.
25.6
36.6 vs.
32.4
1.23 vs.
1.47
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Multivariate analysis
Odds
95%
ratio
confidence
interval
0.09
0.02-0.4

p-value

0.002

0.059

NS

0.008

NS

0.047

NS
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We constructed an additional multivariate model including the driveline
management group, indication for transplant, and type of device. Again, only the
driveline management strategy was independently associated with DLI (OR 0.1,
95% CI 0.03-0.5, p=0.003) and the indication for device placement (i.e. BTT, DT)
as well as type of device placed were not associated with DLI.
Microbiology: The majority of infections were caused by staphylococcal species.
Microbiology of infections was as follows - methicillin-sensitive Staphylococcus
aureus (6), methicillin-resistant S. aureus (2), coagulase-negative staphylococci
(3), one with concurrent Propionibacterium acnes, Streptococcus viridans (1),
Enterobacter cloacae (1), and no culture done (1).
Clinical Outcome of DLI: Among all patients with DLI, concurrent pocket infection
was present in 3, pump/cannula infection manifested as persistent bacteremia
was present in 3, and concurrent mediastinitis in 2. Eight patients underwent
surgical debridement and three required a device exchange secondary to
infection. Majority of the patients were treated with 6-8 weeks of intravenous
antibiotics, though 2 patients required IV antibiotics for >12 weeks, followed by
varying lengths of oral suppression. Among the 14 patients with DLI, six (all were
in Group 1) developed recurrent or new infection with a different organism often
while still on suppressive antibiotics for their first infection. Three patients
required device exchange for thrombosis following the onset of DLI. Five patients
underwent successful heart transplantation following DLI onset.

Discussion
Percutaneous driveline infections are associated with significant morbidity and
mortality, which is especially important since an increasing number of patients
are now receiving VADs for long-term destination therapy. Driveline infection and
bloodstream infections in VAD recipients has been associated with neurologic
complications including cerebrovascular accidents.(11-13) Additionally,
antecedent infection was noted in a third of VAD recipients prior to the
development of device thrombosis and/or hemolysis.(14) Thus, device infection
appears to be associated with greater downstream problems in addition to the
already significant morbidity associated with device infection alone (including
hospital readmission, long courses of intravenous antibiotics, patient discomfort,
decreased quality of life, as well as repeat surgery). Despite all these issues and
the fact that over 15,000 VADS have been implanted worldwide,(15) there is no
consensus on the optimal driveline management protocol, as evidenced by a
recent US survey of VAD centers.(7)
Driveline management consists of driveline stabilization as well as the exit site
cleansing and dressing. In this study, we demonstrated a significant decrease in
DLI in our VAD population by a change in driveline management strategy. We
demonstrated a decrease in DLIs from 1.81 to 0.24 events/ 1000 device days,
which corresponds to a relative risk reduction of 85% and a number needed to
treat of 2.82.
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Silver sulfadiazine, along with chlorhexidine and triclosan, impregnated VAD
driveline has been shown to decrease bacterial colonization in vivo.(16) The
group from Columbia reported results from their use of a sterile silver gauze
driveline dressing (SILVERCEL, Non-Adherent Antimicrobial Alginate Dressing)
along with a Foley anchor device for driveline stabilization and also demonstrated
a significant decrease in DLI with a relative risk reduction of 62.5%.(17) Of note,
our new dressing change protocol did not include sterile technique, yet was
associated with significantly fewer infections than our previous technique or
published data among VAD centers. This is important as adding sterile
technique increases both cost and complexity of dressing changes.
Traditionally an abdominal binder has been used to stabilize the driveline,
despite the fact that it is frequently cumbersome and uncomfortable to use,
potentially leading to decreased outpatient compliance as communicated by
some of our patients. In our updated driveline management strategy, use of a
small anchor made it easier for patients to use at home and potentially ensured
better compliance, though we did not specifically assess compliance in this
retrospective study. Additionally, decreasing the frequency of dressing changes
to every 3 days decreased the physical manipulation of the site with decreased
risk of introduction of infection.
There are currently several approaches to minimizing driveline infections. These
can be broadly categorized under surgical approaches, peri-operative antibiotic
prophylaxis regimens, and approach to the driveline exit site management. The
Driveline Silicone Interface Registry study demonstrated increased freedom from
DLI in subjects implanted with a HeartMate II VAD in whom only the silicone
portion of the DL was externalized; this is the approach used at our center
consistently.(18) Results from the RESIST study were recently published in
abstract form and showed ease of use and increased driveline stability with the
use of a combination dressing kit that consisted of a proprietary “infection
mitigation patch”, a clear dressing, tape and driveline anchor that was used
specifically for patients with HeartMate II devices; additionally driveline dressing
was changed almost weekly. (19) Unfortunately, there has not been a consensus
approach to this process as of yet. We believe that reporting of individual studies
should lead to larger multicenter trials to determine the optimal driveline
management strategy.
There are certain limitations inherent in our retrospective study design. The time
periods of Groups 1 and 2 are not concurrent and thus there is a potential that
the decreased rate of DLI could be related to an “era effect” due to our center’s
increasing comfort level with the devices. However, the main surgeons
performing the procedure did not change in this time period and the operative
approach remained similar as well. Pre- and post-operative management did not
change. An additional possibility is that with the change in driveline management
protocol, there may have been increased focus on the driveline with potential
change in compliance as well as individual technique; however we are unable to
measure this from chart review alone. We made several driveline management
changes at the same time and hence the effect of each individual change on its
own is difficult to gauge. However, similar to the “bundle” effect in decreasing the
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.03
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rates of infection in intravascular catheters, we demonstrate that the bundle of
changes implemented led to a significant decrease in both the overall rate of
infections as well as the incidence of driveline infections/ 1000 device days.
In conclusion, there is a need for multicenter studies evaluating various aspects
of driveline management including stabilization device, type of dressing and
change frequency, as well as cleansing agent. We believe that this study
provides important information that may be used to devise such a multicenter trial
to determine the optimal driveline management strategy for VAD recipients.
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Appendix Table 1. Occurrence of driveline infections (DLI) in the bridge to
transplant (BTT) vs destination therapy (DT) groups of patients. Follow-up
censored at protocol change, device removal/transplant, death or DLI
No. of driveline
infections
DLI incidence/ 1000
device days
DLI incidence/ 100
patient years
Log-rank for infectionfree survival analysis

BTT (n=40)
4 (10%)

DT (n=48)
10 (20.8%)

p-value
0.24

0.52

0.7

0.32

18.9

25.5

0.32
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Appendix Table 2. Occurrence of driveline infections (DLI) based on the type of
device implanted (HeartMate II vs HeartWare). Follow-up censored at protocol
change, device removal/transplant, death or DLI

No. of driveline
infections
DLI incidence/ 1000
device days
DLI incidence/ 100
patient years
Log-rank for infectionfree survival analysis

HeartMate II
(n=64)
13 (20.3%)

HeartWare
(n=24)
1 (4.2%)

p-value

0.74

0.23

0.12

26.8

8.3

0.12
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0.1

1.64
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